Regenxbio Inc (RGNX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | -71.48% | -70.70% | 69.06% | 60.30% | -12.84% |
| Operating profit margin | -313.29% | -293.81% | 35.82% | -40.94% | -250.16% |
| Pretax margin | -308.05% | -313.41% | 31.62% | -36.40% | -163.67% |
| Net profit margin | -307.87% | -313.31% | 28.62% | -38.20% | -159.05% |
Regenxbio Inc's profitability ratios have displayed significant fluctuations over the past five years. The gross profit margin, which measures the percentage of revenue that exceeds the cost of goods sold, has shown a decreasing trend from 2019 to 2022 but rebounded in 2023. This indicates that the company has been able to improve its production efficiency in the most recent year.
However, the operating profit margin reflects the company's ability to control operating expenses in relation to its revenue. The negative values for 2020, 2022, and 2023 suggest that Regenxbio Inc has been experiencing significant losses from its core operations in these years. Particularly, the substantial decline in 2020 raises concerns about the company's operational performance and cost management.
Furthermore, the pretax margin and net profit margin, which indicate the company's profitability before and after accounting for taxes, respectively, both show a similar pattern of negative values across the years. This implies that besides operational challenges, Regenxbio Inc has been struggling to generate profits after accounting for taxes and other expenses.
Overall, the company's profitability ratios reveal a mixed performance, with improvements in gross profit margin in 2023 but persistent challenges in operating profitability and overall net profitability that require further assessment and strategic adjustments to enhance long-term financial sustainability.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -46.71% | -31.55% | 14.36% | -16.84% | -29.92% |
| Return on assets (ROA) | -45.91% | -33.64% | 11.48% | -15.71% | -19.03% |
| Return on total capital | -82.37% | -49.82% | 21.92% | -27.86% | -33.10% |
| Return on equity (ROE) | -84.52% | -54.31% | 16.73% | -29.45% | -21.04% |
Regenxbio Inc's profitability ratios have shown significant fluctuations over the past five years.
1. Operating return on assets (Operating ROA) has been negative over the period, indicating that the company is not efficiently utilizing its assets to generate operating profits. The ratio decreased from -29.93% in 2019 to -46.71% in 2023, showing a worsening trend in operational efficiency.
2. Return on assets (ROA) also remained negative throughout the period, indicating that the company is not effectively generating profits from its total assets. The ratio deteriorated from -19.03% in 2019 to -45.91% in 2023, suggesting a decline in overall profitability.
3. Return on total capital has shown significant fluctuations, ranging from -86.01% in 2023 to 20.93% in 2021. This ratio reflects the company's ability to generate returns for both equity and debt holders. The negative values in recent years indicate that the company's total capital has not been effectively utilized to generate profits.
4. Return on equity (ROE) has also been negative over the period, indicating that the company's shareholders are not earning returns on their equity investments. The ratio decreased from -21.04% in 2019 to -84.52% in 2023, suggesting a significant decline in shareholder value.
Overall, Regenxbio Inc's profitability ratios paint a concerning picture of the company's financial performance, with consistent negative returns across different metrics. This indicates a lack of profitability and efficiency in utilizing assets and capital to generate returns for shareholders. Further analysis and strategic interventions may be necessary to improve the company's financial health and profitability.